Results 71 to 80 of about 1,744 (184)

Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments

Life, 2023
Oritavancin is a long-acting lipoglycopeptide with in vitro activity against Gram-positive pathogens, as well as good bactericidal activity and sterilisation ability in biofilm. It has been approved for acute bacterial skin and skin structure infections (
Tommaso Lupia, Ilaria De Benedetto, Roberta Bosio, Nour Shbaklo, Francesco Giuseppe De Rosa, Silvia Corcione   +5 more
doaj   +1 more source

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

Angewandte Chemie International Edition, Volume 64, Issue 10, March 3, 2025.
This article provides an overview over antibacterial drugs investigated in the past three decades. Aspects of the compound's origins, their cellular targets, the antibacterial spectrum and proof‐of‐concept in animal studies are covered and current trends are highlighted.
Roderich D. Süssmuth, Marcel Kulike‐Koczula, Peng Gao, Simone Kosol   +3 more
wiley   +1 more source

NIR‐II emissive biohybrid nanovesicles as mild‐temperature photothermal antibiofilm agents against acute bacterial skin and skin‐structure infections

Interdisciplinary Medicine, Volume 3, Issue 1, January 2025.
A new NIR‐II emissive biohybrid nanovesicle (nano‐MBA) was designed as a mild‐temperature photothermal antibiofilm agent against acute bacterial skin and skin‐structure infections, enabling AIEgen‐based photothermal therapy and biofilm degradation treatment at a safe temperature (50°C).
Ji Wang, Zhihao Wu, Xiaoxi Ma, Zhihui Huang, Haorong Dong, Jinxin Zhang, Xiaoming Liu, Pengfei Zhang, Shuhuai Yao   +8 more
wiley   +1 more source

Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use

Drugs in Context
Background: Oritavancin is a long-acting lipoglycopeptide antibiotic approved for acute bacterial skin and skin structure infections (ABSSSI) with potential applicability across difficult-to-treat Gram-positive infections such as osteomyelitis ...
Alex Soriano, Carlo Tascini, Marco Falcone, Laura Morata, Marco Bongiovanni, Federico Pea, Pierluigi Viale   +6 more
doaj   +1 more source

Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project [PDF]

, 2021
[Introduction] Ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam and ceftolozane-tazobactam are novel antibiotics used to treat infections caused by multidrug-resistant pathogens (MDR).
Anguita-Santos, Francisco, Aznarte-Padial, M. Pilar, Borreguero, Irene, Castón, Juan J., Corzo, Juan E., Esteban-Moreno, M. Ángeles, Herrero-Rodríguez, Carmen, Jiménez-Aguilar, Patricia, López-Cárdenas, Salvador, Maldonado, Natalia, Martín-Aspas, Andrés, Martínez Marcos, Francisco Javier, Ojeda Burgos, Guillermo, Palacios-Baena, Zaira Raquel, Praena-Segovia, Julia, Retamar Gentil, Pilar, Rodríguez-Baño, Jesús, Rosso-Fernández, Clara, Valiente de Santis, Lucía   +18 more
core   +1 more source

Dalbavancin to Complete a Prolonged Antibiotic Course for Persistent Bacillus cereus Bacteremia: A Case Report and Literature Review

Case Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Bacillus cereus is a Gram‐positive, rod‐shaped facultative anaerobe commonly associated with gastrointestinal infections. Although typically regarded as a blood culture contaminant, B. cereus can cause severe infections, including bacteremia, in high‐risk patients.
Jahnavi Yetukuri, Joseph Choi, Andrew Darkow, Larry M. Bush   +3 more
wiley   +1 more source

Efficacy and safety of vancomycin compared with those of alternative treatments for methicillin‐resistant Staphylococcus aureus infections: An umbrella review

Journal of Evidence-Based Medicine, Volume 17, Issue 4, Page 729-739, December 2024.
Abstract Objective To summarize the evidence on the efficacy and safety of vancomycin compared with those of alternative treatments in adult patients with methicillin‐resistant Staphylococcus aureus (MRSA) infection. Methods PubMed, Embase, and Web of Science were searched up to December 15, 2023, for systematic reviews and meta‐analyses comparing ...
Sujata Purja, Minji Kim, Yomna Elghanam, Hae Jung Shim, Eunyoung Kim   +4 more
wiley   +1 more source

Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience

Antibiotics
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are marked by substantial morbidity, frequent need for hospitalization, and long courses of intravenous antibiotic therapy. Herein, we report four cases of pediatric patients admitted for ABSSSI
Sara Maria Scarano, Eugenia Bruzzese, Marco Poeta, Margherita Del Bene, Alfredo Guarino, Andrea Lo Vecchio   +5 more
doaj   +1 more source

Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019

Journal of Global Antimicrobial Resistance, 2021
: Objectives: Omadacycline was tested against 7000 bacterial isolates collected prospectively from medical centres in the USA during 2019. Methods: Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards ...
Michael A. Pfaller, Michael D. Huband, Dee Shortridge, Robert K. Flamm   +3 more
doaj   +1 more source

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections

Infectious Diseases and Therapy, 2019
Introduction Dalbavancin is approved for acute bacterial skin and skin structure infections (ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive infections.
Jacqueline T. Bork, Emily L. Heil, Shanna Berry, Eurides Lopes, Rohini Davé, Bruce L. Gilliam, Anthony Amoroso   +6 more
doaj   +1 more source